Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
+$0.31 today
- Market cap
- $1.21B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
Volume 0.00M
Average 0.01M
AAPG Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Ascentage Pharma Group InternationalNASDAQ: AAPG
Operating Expenses · Q4 FY2025 · quarter ended Dec 2025
Operating expenses grows 27.7% year over year
Q4 FY2025 operating expenses of CN¥906.3M rose 27.7% year over year. Over 3 fiscal years it compounded at +15.7% a year.
Context
- Operating expenses amounted to 287.6% of revenue in FY2025, up 152.8 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
CNY · from the income statement
- Latest · FY2025
- 1.61B CNY
- Year-over-year change
- +21.5%
- 4-year CAGR
- +13.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.61B | +21.5% |
| FY2024 | 2024-12-31 | 1.32B | +24.2% |
| FY2023 | 2023-12-31 | 1.06B | +2.6% |
| FY2022 | 2022-12-31 | 1.04B | +8.3% |
| FY2021 | 2021-12-31 | 957.75M | — |
Operating Expenses vs competitors
How AAPG compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +21.5% is the 5th highest of 10, against a peer median of +11.7%.
- Operating expenses amounts to 287.6% of revenue for AAPG, versus a peer median of 174.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥1.61B CNY | +21.5% | +15.7% | 287.6% |
| LTM Jun 2026 | $517.9M USD | +0.8% | -3.3% | 115.2% | |
| LTM Aug 2026 | $317.52M USD | +142.5% | +109.8% | 45.2% | |
| LTM Jun 2026 | $297.23M USD | +30.0% | +30.7% | 174.9% | |
| LTM Sep 2026 | $227.59M USD | +29.2% | +8.0% | — | |
| LTM Mar 2026 | $212.38M USD | +50.5% | +37.4% | 428.3% | |
| LTM Mar 2026 | $163.78M USD | -44.2% | +49.7% | 72.7% | |
| LTM Mar 2026 | $156.87M USD | +11.7% | +68.8% | — | |
| LTM Mar 2026 | $146.9M USD | -2.4% | -6.2% | 421.4% | |
| LTM Jun 2024 | $68.58M USD | — | -15.4% | 1056.8% | |
| LTM Mar 2026 | $58.43M USD | -8.8% | +4.2% | — | |
| Peer median (excluding AAPG) | — | +11.7% | +19.4% | 174.9% | |
Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.91M | 209.71M | 221.98M | 980.65M | 558.48M |
| Cost of Revenue | 3.33M | 22M | 30.54M | 29.09M | 131.73M |
| Gross Profit | 24.58M | 187.71M | 191.44M | 951.57M | 426.75M |
| Gross Margin | 88.1% | 89.5% | 86.2% | 97.0% | 76.4% |
| Research & Development | 766.49M | 743.1M | 706.97M | 947.25M | 1.08B |
| Selling, General & Admin | 191.26M | 328.02M | 376.46M | 383.12M | 522.67M |
| Operating Expenses | 957.75M | 1.04B | 1.06B | 1.32B | 1.61B |
| Depreciation & Amortization | 17.18M | 47.42M | 93.2M | 93.17M | 84.12M |
| EBITDA | (798.34M) | (786.97M) | (743.61M) | (237.63M) | (1.1B) |
| EBITDA Margin | -2860.4% | -375.3% | -335.0% | -24.2% | -196.1% |
| Operating Income | (869.84M) | (849.81M) | (872.64M) | (369.73M) | (1.18B) |
| Operating Margin | -3116.6% | -405.2% | -393.1% | -37.7% | -211.1% |
| Interest Income | 7.11M | 9.73M | 32.41M | 37.84M | 79.89M |
| Interest Expense | 16.73M | 52.79M | 96.06M | 64.46M | 52.6M |
| Other Income / Expenses | 37.59M | (37.36M) | (60.23M) | (25.53M) | (23.21M) |
| Income Before Tax | (832.25M) | (887.17M) | (932.86M) | (395.26M) | (1.2B) |
| Pre-Tax Margin | -2981.9% | -423.0% | -420.2% | -40.3% | -215.3% |
| Income Tax Expense | (49.83M) | (4.25M) | (7.15M) | 10.43M | 6.75M |
| Net Income | (782.42M) | (882.92M) | (925.64M) | (405.43M) | (1.21B) |
| Net Margin | -2803.4% | -421.0% | -417.0% | -41.3% | -216.5% |
| EPS (Basic) | (49.12) | (53.60) | (52.48) | (5.36) | (13.56) |
| EPS (Diluted) | (49.12) | (53.60) | (52.48) | (5.36) | (13.56) |
| Weighted Avg Shares | 15.91M | 16.48M | 17.64M | 75.52M | 89.03M |
| Weighted Avg Shares (Diluted) | 15.91M | 16.48M | 17.64M | 75.52M | 89.03M |
Ascentage Pharma Group International
NASDAQ:AAPG
Intrinsic Alpha fair value
Locked
Current Price
$13.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.